Defective expression of SIRT1 contributes to sustain inflammatory pathways in the gut

Mucosal Immunology

Volumn 7, Issue 6, 2014, Pages 1467-1479

  Caruso, R ^a   Marafini, I ^a   Franze E ^a   Stolfi, C ^a   Zorzi, F ^a   Monteleone, I ^a   Caprioli, F ^b   Colantoni, A ^a   Sarra, M ^a   Sedda, S ^a   Biancone, L ^a   Sileri, P ^a   Sica, G S ^a   Macdonald, T T ^c   Pallone, F ^a   Monteleone, G ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BUDESONIDE; CAY 10591; CD19 ANTIGEN; CD3 ANTIGEN; CORTICOSTEROID; ENZYME ACTIVATOR; ENZYME INHIBITOR; EX 527; GAMMA INTERFERON; HLA DR2 ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOMODULATING AGENT; INFLIXIMAB; INTERLEUKIN 17; INTERLEUKIN 21; MESALAZINE; NEUTRALIZING ANTIBODY; OXAZOLONE; RNA; SIRTUIN 1; TRANSCRIPTION FACTOR RELA; TRINITROBENZENESULFONIC ACID; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG; IFNG PROTEIN, HUMAN; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN DERIVATIVE; MONOCLONAL ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; SIRT1 PROTEIN, HUMAN; SIRT1 PROTEIN, MOUSE;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CLINICAL ARTICLE; COLITIS; COLORECTAL SURGERY; CONTROLLED STUDY; CROHN DISEASE; CYTOKINE PRODUCTION; DISEASE EXACERBATION; DOWN REGULATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; INFLAMMATORY BOWEL DISEASE; INHIBITION KINETICS; INTESTINE BIOPSY; INTESTINE MUCOSA; LAMINA PROPRIA; MALE; MONONUCLEAR CELL; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; T LYMPHOCYTE; TREATMENT OUTCOME; ULCERATIVE COLITIS; UPREGULATION; VERY ELDERLY; YOUNG ADULT; ANIMAL; CHEMICALLY INDUCED; CLINICAL TRIAL; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; INFLAMMATORY BOWEL DISEASES; INTESTINE; MIDDLE AGED; PATHOLOGY;

ADJUVANTS, IMMUNOLOGIC; ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; INFLAMMATORY BOWEL DISEASES; INTERFERON-GAMMA; INTERLEUKINS; INTESTINES; MALE; MICE; MIDDLE AGED; OXAZOLONE; SIRTUIN 1; TRINITROBENZENESULFONIC ACID; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84908216047     PISSN: 19330219     EISSN: 19353456     Source Type: Journal    
DOI: 10.1038/mi.2014.35     Document Type: Article

References (46)

1. Kaser, A, Zeissig, S & Blumberg, R. S. Inflammatory bowel disease. Annu. Rev. Immunol. 28, 573-621 (2010).
2. Xavier, R. J. & Podolsky, D. K. Unravelling the pathogenesis of inflammatory bowel disease. Nature 448, 427-434 (2007).
3. Strober, W, Fuss, I & Mannon, P. The fundamental basis of inflammatory bowel disease. J. Clin. Invest. 117, 514-521 (2007).
4. Bouma, G & Strober, W. The immunological and genetic basis of inflammatory bowel disease. Nat. Rev. Immunol. 3, 521-533 (2003).
5. Strober, W & Fuss, I. J. Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases. Gastroenterology 140, 1756-1767 (2011).
6. Imai, S, Armstrong, C. M., Kaeberlein, M & Guarente, L. Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature 403, 795-800 (2000).
7. Landry, J. et al. The silencing protein SIR2 and its homologs are NAD-dependent protein deacetylases. Proc. Natl Acad. Sci. USA 97, 5807-5811 (2000).
8. Vaquero, A, Scher, M, Lee, D, Erdjument-Bromage, H, Tempst, P & Reinberg, D. Human SirT1 interacts with histone H1 and promotes formation of facultative heterochromatin. Mol. Cell 16, 93-105 (2004).
9. Bordone, L & Guarente, L. Calorie restriction, SIRT1 and metabolism: understanding longevity. Nat. Rev. Mol. Cell Biol. 6, 298-305 (2005).
10. North, B. J. & Verdin, E. Sirtuins: Sir2-related NAD-dependent protein deacetylases. Genome Biol. 5, 224 (2004).
11. Afshar,G& Murnane, J. P. Characterization of a human genewith sequence homology to Saccharomyces cerevisiae SIR2. Gene 234, 161-168 (1999).
12. Zhang, J. et al. The type III histone deacetylase Sirt1 is essential for maintenance of T cell tolerance in mice. J. Clin. Invest. 119, 3048-3058 (2009).
13. Kume, S. et al. SIRT1 inhibits transforming growth factor beta-induced apoptosis in glomerular mesangial cells via Smad7 deacetylation. J. Biol. Chem. 282, 151-158 (2007).
14. Schug, T. T. et al. Myeloid deletion of SIRT1 induces inflammatory signaling in response to environmental stress. Mol. Cell. Biol. 30, 4712-4721 (2010).
15. Schreiber, S, Nikolaus, S & Hampe, J. Activation of nuclear factor kappa B inflammatory bowel disease. Gut 42, 477-484 (1998).
16. Neurath, M. F. et al. Cytokine gene transcription by NF-kappa B family members in patients with inflammatory bowel disease. Ann. N. Y. Acad. Sci. 859, 149-159 (1998).
17. Fuss, I. J. et al. Disparate CD4 lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J. Immunol. 157, 1261-1270 (1996).
18. Brand, S. Crohn's disease: Th1, Th17 or both? The change of a paradigm: new immunological and genetic insights implicate Th17 cells in the pathogenesis of Crohn's disease. Gut 58, 1152-1167 (2009).
19. Monteleone, G. et al. Interleukin-21 enhances T-helper cell type I signaling and interferon-gamma production in Crohn's disease. Gastroenterology 128, 687-694 (2005).
20. Fina, D. et al. Regulation of gut inflammation and th17 cell response by interleukin-21. Gastroenterology 134, 1038-1048 (2008).
21. Heller, F. et al. Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. Gastroenterology 129, 550-564 (2005).
22. Neurath, M. F., Fuss, I, Kelsall, B. L., Stuber, E & Strober, W. Antibodies to interleukin 12 abrogate established experimental colitis in mice. J. Exp. Med. 182, 1281-1290 (1995).
23. Boirivant, M, Fuss, I. J., Chu, A & Strober, W. Oxazolone colitis: a murine model of T helper cell type 2 colitis treatable with antibodies to interleukin 4. J. Exp. Med. 188, 1929-1939 (1998).
24. Heller, F, Fuss, I. J., Nieuwenhuis, E. E., Blumberg, R. S. & Strober, W. Oxazolone colitis, a Th2 colitis model resembling ulcerative colitis, is mediated by IL-13-producing NK-T cells. Immunity 17, 629-638 (2002).
25. Mudter, J. et al. The transcription factor IFN regulatory factor-4 controls experimental colitis in mice via T cell-derived IL-6. J. Clin. Invest. 118, 2415-2426 (2008).
26. Kong, S, McBurney, M. W. & Fang, D. Sirtuin 1 in immune regulation and autoimmunity. Immunol. Cell Biol. 90, 6-13 (2012).
27. Tursi, A. et al. Musosal tumour necrosis factor alpha in diverticular disease of the colon is overexpressed with disease severity. Colorectal Dis. 14, e258-e263 (2012).
28. Caruso, R. et al. Analysis of the cytokine profile in the duodenal mucosa of refractory coeliac disease patients. Clin. Sci. (Lond) 126, 451-458 (2014).
29. Rajendrasozhan, S, Yang, S. R., Kinnula, V. L. & Rahman, I. SIRT1, an antiinflammatory and antiaging protein, is decreased in lungs of patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 177, 861-870 (2008).
30. Biason-Lauber, A. et al. Identification of a SIRT1 mutation in a family with type 1 diabetes. Cell Metab. 17, 448-455 (2013).
31. Nayagam, V. M. et al. SIRT1 modulating compounds from high-throughput screening as anti-inflammatory and insulin-sensitizing agents. J. Biomol. Screen. 11, 959-967 (2006).
32. Napper, A. D. et al. Discovery of indoles as potent and selective inhibitors of the deacetylase SIRT1. J. Med. Chem. 48, 8045-8054 (2005).
33. Yang, H. et al. SIRT1 activators suppress inflammatory responses through promotion of p65 deacetylation and inhibition of NF-kappaB activity. PLoS One 7, e46364 (2012).
34. Gardner, P. J., Joshi, L, Lee, R. W., Dick, A. D., Adamson, P & Calder, V. L. SIRT1 activation protects against autoimmune Tcell-driven retinal disease in mice via inhibition of IL-2/Stat5 signaling. J. Autoimmun. 42, 117-129 (2013).
35. Singh, U. P. et al. Resveratrol (trans-3,5,4'-trihydroxystilbene) induces silent mating type information regulation-1 and down-regulates nuclear transcription factor-kappaB activation to abrogate dextran sulfate sodiuminduced colitis. J. Pharmacol. Exp. Ther. 332, 829-839 (2010).
36. Martin, A. R., Villegas, I, Sanchez-Hidalgo, M & de la Lastra, C. A. The effects of resveratrol, a phytoalexin derived from red wines, on chronic inflammation induced in an experimentally induced colitis model. Br. J. Pharmacol. 147, 873-885 (2006).
37. Martin, A. R., Villegas, I, La Casa, C & de la Lastra, C. A. Resveratrol, a polyphenol found in grapes, suppresses oxidative damage and stimulates apoptosis during early colonic inflammation in rats. Biochem. Pharmacol. 67, 1399-1410 (2004).
38. Hilliard, B. A. et al. Critical roles of c-Rel in autoimmune inflammation and helper T cell differentiation. J. Clin. Invest. 110, 843-850 (2002).
39. Akimova, T. et al. Targeting sirtuin-1 alleviates experimental autoimmune colitis by induction of Foxp3 T-regulatory cells. Mucosal Immunol. advance online publication, 19 February 2014; doi:10. 1038/mi. 2014. 10 (2014) (e-pub ahead of print).
40. Daperno, M. et al. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. Gastrointest. Endosc. 60, 505-512 (2004).
41. Schroeder, K. W., Tremaine, W. J. & Ilstrup, D. M. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N. Engl. J. Med. 317, 1625-1629 (1987).
42. Marsh, M. N. Gluten, major histocompatibility complex, and the small intestine. A molecular and immunobiologic approach to the spectrum of gluten sensitivity ('celiac sprue'). Gastroenterology 102, 330-354 (1992).
43. Monteleone, G. et al. Interleukin 12 is expressed and actively released by Crohn's disease intestinal lamina propria mononuclear cells. Gastroenterology 112, 1169-1178 (1997).
44. Caruso, R. et al. A functional role for interleukin-21 in promoting the synthesis of the T-cell chemoattractant, MIP-3alpha, by gut epithelial cells. Gastroenterology 132, 166-175 (2007).
45. Boirivant, M. et al. Inhibition of Smad7 with a specific antisense oligonucleotide facilitates TGF-beta1-mediated suppression of colitis. Gastroenterology 131, 1786-1798 (2006).
46. Stolfi, C. et al. Involvement of interleukin-21 in the regulation of colitisassociated colon cancer. J. Exp. Med. 208, 2279-2290 (2011).